[1]
|
Browder, T., Butterfield, C.E., Kräling, B.M., Shi, B., Marshall, B., O’Reilly, M.S. and Folkman, J. (2000) Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-Resistant Cancer. Cancer Research, 60, 1878-1886.
|
[2]
|
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D.J., Bohlen, P. and Kerbel, R.S. (2006) Continuous Low-Dose Therapy with Vinblastine and VEGF Receptor-2 Antibody Induces Sustained Tumor Regression without Overt Toxicity. Journal of Clinical Investigation, 105, R15-R24. https://doi.org/10.1172/JCI8829
|
[3]
|
Hanahan, D., Bergers, G. and Bergsland, E. (2000) Less Is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice. Journal of Clinical Investigation, 105, 1045-1047.
https://doi.org/10.1172/JCI9872
|
[4]
|
Kerbel, R.S. (2015) A Decade of Experience in Developing Preclinical Models of Advanced or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemo-Therapy, and the Tumor Microenvironment. The Cancer Journal, 21, 274-283. https://doi.org/10.1097/PPO.0000000000000134
|
[5]
|
Cazzaniga, M.E., Cordani, N., Capici, S., Cogliati, V., Riva, F. and Cerrito, M.G. (2021) Metronomic Chemotherapy. Cancers (Basel), 13, 2236. https://doi.org/10.3390/cancers13092236
|
[6]
|
Nasr, K.E., Osman, M.A., Elkady, M.S. and Ellithy, M.A. (2015) Metronomic Methotrexate and Cyclophosphamide after Carboplatin Included Adjuvant Chemotherapy in Triple Negative Breast Cancer: A Phase III Study. Annals of Translational Medicine, 3, 284.
|
[7]
|
Montagna, E., Bagnardi, V., Cancello, G., et al. (2018) Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. Breast Care (Basel), 13, 177-181.
https://doi.org/10.1159/000487630
|
[8]
|
Wang, X., Wang, S., Huang, H., et al. (2021) Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients with Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA, 325, 50-58.
https://doi.org/10.1001/jama.2020.23370
|
[9]
|
Johnston, S.R. (2010) New Strategies in Estrogen Receptor-Positive Breast Cancer. Clinical Cancer Research, 16, 1979-1987. https://doi.org/10.1158/1078-0432.CCR-09-1823
|
[10]
|
Schwartzberg, L.S., Wang, G., Somer, B.G., Blakely, L.J., Wheeler, B.M., Walker, M.S., Stepanski, E.J. and Houts, A.C. (2014) Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer, 14, 13-19.
https://doi.org/10.1016/j.clbc.2013.09.003
|
[11]
|
Li, J.W., Zuo, W.J., Ivanova, D., Jia, X.Q., Lei, L. and Liu, G.Y. (2019) Metronomic Capecitabine Combined with Aromatase Inhibitors for New Chemoendocrine Treatment of Advanced Breast Cancer: A Phase II Clinical Trial. Breast Cancer Research and Treatment, 173, 407-415. https://doi.org/10.1007/s10549-018-5024-3
|
[12]
|
Wildiers, H., Tryfonidis, K., Dal Lago, L., Vuylsteke, P., Curigliano, G., Waters, S., Brouwers, B., Altintas, S., Touati, N., Cardoso, F. and Brain, E. (2018) Pertuzumab and Trastuzumab with or without Metronomic Chemotherapy for Older Patients with HER2-Positive Metastatic Breast Cancer (EORTC 75111-10114): An Open-Label, Randomised, Phase 2 Trial from the Elderly Task Force/Breast Cancer Group. The Lancet Oncology, 19, 323-336.
https://doi.org/10.1016/S1470-2045(18)30083-4
|
[13]
|
Wang, Z., Liu, J., Ma, F., et al. (2021) Safety and Efficacy Study of Oral Metronomic Vinorelbine Combined with Trastuzumab (mNH) in HER2-Positive Metastatic Breast Cancer: A Phase II Trial. Breast Cancer Research and Treatment, 188, 441-447. https://doi.org/10.1007/s10549-021-06216-5
|
[14]
|
Fedele, P., Marino, A., Orlando, L., et al. (2012) Efficacy and Safety of Low-Dose Metronomic Chemotherapy with Capecitabine in Heavily Pretreated Patients with Metastatic Breast Cancer. European Journal of Cancer, 48, 24-29.
https://doi.org/10.1016/j.ejca.2011.06.040
|
[15]
|
Palazzo, A., Dellapasqua, S., Munzone, E., et al. (2018) Phase II Trial of Bevacizumabplus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide with or without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. Clinical Breast Cancer, 18, 328-335.
https://doi.org/10.1016/j.clbc.2018.01.010
|